share_log

信達生物:首席財務官退休及委任新任首席財務官

INNOVENT BIO: RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER

香港交易所 ·  Feb 5 03:30
Summary by Moomoo AI
信達生物製藥有限公司宣佈,自2024年2月5日起,奚浩先生將退休離任首席財務官職位,但仍將留任執行董事並參與董事會戰略與業務決策。奚浩先生自2017年加入公司以來,對公司的戰略制定、公司治理、財務管理和業務發展做出了顯著貢獻,並成功領導公司在香港聯合交易所有限公司主板上市及後續融資活動。同時,董事會宣佈由飛女士將接任新的首席財務官,由飛女士具有超過20年的財務管理和戰略投資經驗,曾在錦欣生殖醫療集團有限公司及三生製藥等公司擔任高級職位。董事會對奚浩先生的貢獻表示感謝,並對由飛女士的加入表示歡迎,期待她能助力公司實現使命和願景。
信達生物製藥有限公司宣佈,自2024年2月5日起,奚浩先生將退休離任首席財務官職位,但仍將留任執行董事並參與董事會戰略與業務決策。奚浩先生自2017年加入公司以來,對公司的戰略制定、公司治理、財務管理和業務發展做出了顯著貢獻,並成功領導公司在香港聯合交易所有限公司主板上市及後續融資活動。同時,董事會宣佈由飛女士將接任新的首席財務官,由飛女士具有超過20年的財務管理和戰略投資經驗,曾在錦欣生殖醫療集團有限公司及三生製藥等公司擔任高級職位。董事會對奚浩先生的貢獻表示感謝,並對由飛女士的加入表示歡迎,期待她能助力公司實現使命和願景。
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT MR. CHI-HO WILL RETIRE AS CHIEF FINANCIAL OFFICER FROM FEBRUARY 5, 2024, BUT WILL REMAIN AN EXECUTIVE DIRECTOR AND PARTICIPATE IN THE BOARD'S STRATEGIC AND BUSINESS DECISIONS. SINCE JOINING THE COMPANY IN 2017, MR. CHI-HO HAS MADE SIGNIFICANT CONTRIBUTIONS TO THE COMPANY'S STRATEGY, CORPORATE GOVERNANCE, FINANCIAL MANAGEMENT AND BUSINESS DEVELOPMENT, AND SUCCESSFULLY LED THE COMPANY'S LISTING AND SUBSEQUENT FINANCING ACTIVITIES ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE LIMITED. At the same time, the Board of Directors announced that Ms. Fei will be appointed as the new Chief Financial Officer. Ms. Fei has more than 20 years of financial management and strategic investment experience and has held senior positions at such companies as Kam Hin Reproductive Medical Group Limited and Sansheng Pharmaceuticals. The Board of Directors is grateful for Mr. Chi-ho's contributions and welcomes Ms. Fei's participation, and looks forward to helping the company achieve its mission and vision.
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT MR. CHI-HO WILL RETIRE AS CHIEF FINANCIAL OFFICER FROM FEBRUARY 5, 2024, BUT WILL REMAIN AN EXECUTIVE DIRECTOR AND PARTICIPATE IN THE BOARD'S STRATEGIC AND BUSINESS DECISIONS. SINCE JOINING THE COMPANY IN 2017, MR. CHI-HO HAS MADE SIGNIFICANT CONTRIBUTIONS TO THE COMPANY'S STRATEGY, CORPORATE GOVERNANCE, FINANCIAL MANAGEMENT AND BUSINESS DEVELOPMENT, AND SUCCESSFULLY LED THE COMPANY'S LISTING AND SUBSEQUENT FINANCING ACTIVITIES ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE LIMITED. At the same time, the Board of Directors announced that Ms. Fei will be appointed as the new Chief Financial Officer. Ms. Fei has more than 20 years of financial management and strategic investment experience and has held senior positions at such companies as Kam Hin Reproductive Medical Group Limited and Sansheng Pharmaceuticals. The Board of Directors is grateful for Mr. Chi-ho's contributions and welcomes Ms. Fei's participation, and looks forward to helping the company achieve its mission and vision.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more